{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tanezumab+IV", "query": { "intervention": "Tanezumab IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tanezumab+IV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T05:17:09.655Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00784693", "title": "A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Tanezumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 48, "start_date": "2008-12-18", "completion_date": "2010-04-05", "has_results": true, "last_update_posted_date": "2021-04-30", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 30, "location_summary": "Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784693" }, { "nct_id": "NCT00584870", "title": "RN624 In Adult Patients With Chronic Low Back Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Back Pain" ], "interventions": [ { "name": "Naproxen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04383119 (RN624)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 220, "start_date": "2007-07-05", "completion_date": "2008-09-02", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 38, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00584870" }, { "nct_id": "NCT00809354", "title": "Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis", "Arthritis" ], "interventions": [ { "name": "NSAID", "type": "DRUG" }, { "name": "tanezumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2720, "start_date": "2009-02-12", "completion_date": "2011-01-12", "has_results": true, "last_update_posted_date": "2021-06-24", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 250, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809354" }, { "nct_id": "NCT00788294", "title": "Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "tanezumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 76, "start_date": "2008-11", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788294" }, { "nct_id": "NCT00924664", "title": "Long Term Safety Study of Tanezumab in Chronic Low Back Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Back Pain" ], "interventions": [ { "name": "Tanezumab 20 mg", "type": "BIOLOGICAL" }, { "name": "Tanezumab 10 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 849, "start_date": "2009-08-20", "completion_date": "2011-06-22", "has_results": true, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 149, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hueytown", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924664" }, { "nct_id": "NCT01089725", "title": "Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis", "Arthritis", "Pain" ], "interventions": [ { "name": "Placebo IV", "type": "BIOLOGICAL" }, { "name": "Placebo SC", "type": "BIOLOGICAL" }, { "name": "Tanezumab SC", "type": "BIOLOGICAL" }, { "name": "Tanezumab IV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 385, "start_date": "2010-03-30", "completion_date": "2011-02-18", "has_results": true, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 91, "location_summary": "Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01089725" }, { "nct_id": "NCT00545129", "title": "A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasm Metastasis", "Palliative Care" ], "interventions": [ { "name": "Tanezumab 10 mg IV", "type": "DRUG" }, { "name": "IV Placebo for tanezumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2009-04-29", "completion_date": "2012-02-07", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 12, "location_summary": "La Jolla, California • South Bend, Indiana • Shreveport, Louisiana + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545129" }, { "nct_id": "NCT00733902", "title": "Tanezumab in Osteoarthritis of the Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Osteoarthritis" ], "interventions": [ { "name": "tanezumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 697, "start_date": "2008-09-15", "completion_date": "2010-01-14", "has_results": true, "last_update_posted_date": "2021-03-22", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 82, "location_summary": "Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733902" }, { "nct_id": "NCT00744471", "title": "Tanezumab in Osteoarthritis Of The Hip", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Osteoarthritis", "Osteoarthritis, Hip" ], "interventions": [ { "name": "tanezumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 627, "start_date": "2008-11-17", "completion_date": "2010-08-13", "has_results": true, "last_update_posted_date": "2021-02-26", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 99, "location_summary": "Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00744471" }, { "nct_id": "NCT00960804", "title": "Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoarthritis" ], "interventions": [ { "name": "Tanezumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 21, "start_date": "2010-02-15", "completion_date": "2010-11-11", "has_results": true, "last_update_posted_date": "2021-02-08", "last_synced_at": "2026-09-09T05:17:09.655Z", "location_count": 18, "location_summary": "Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more", "locations": [ { "city": "Atlantis", "state": "Florida" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960804" } ] }